| 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus M Aringer, K Costenbader, D Daikh, R Brinks, M Mosca, ... Arthritis & rheumatology 71 (9), 1400-1412, 2019 | 2687 | 2019 |
| EULAR recommendations for the management of Behçet disease G Hatemi, A Silman, D Bang, B Bodaghi, AM Chamberlain, A Gul, ... Annals of the rheumatic diseases 67 (12), 1656-1662, 2008 | 995 | 2008 |
| Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study S Dass, SJ Bowman, EM Vital, K Ikeda, CT Pease, J Hamburger, ... Annals of the rheumatic diseases 67 (11), 1541-1544, 2008 | 458 | 2008 |
| Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian, EM Vital, TL Ford, ... The Lancet Rheumatology 1 (4), e208-e219, 2019 | 352 | 2019 |
| Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination A Watad, G De Marco, H Mahajna, A Druyan, M Eltity, N Hijazi, A Haddad, ... Vaccines 9 (5), 435, 2021 | 345 | 2021 |
| Development of psoriasis after B cell depletion with rituximab S Dass, EM Vital, P Emery Arthritis & Rheumatism 56 (8), 2715-2718, 2007 | 288 | 2007 |
| Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts C Díaz-Lagares, S Croca, S Sangle, EM Vital, F Catapano, ... Autoimmunity reviews 11 (5), 357-364, 2012 | 283 | 2012 |
| Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis S Dass, AC Rawstron, EM Vital, K Henshaw, D McGonagle, P Emery Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 256 | 2008 |
| B cell biomarkers of rituximab responses in systemic lupus erythematosus EM Vital, S Dass, MH Buch, K Henshaw, CT Pease, MF Martin, F Ponchel, ... Arthritis & Rheumatism 63 (10), 3038-3047, 2011 | 250 | 2011 |
| Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre MY Md Yusof, A Kabia, M Darby, G Lettieri, P Beirne, EM Vital, S Dass, ... Rheumatology 56 (8), 1348-1357, 2017 | 204 | 2017 |
| Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy A Psarras, P Emery, EM Vital Rheumatology 56 (10), 1662-1675, 2017 | 173 | 2017 |
| Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re‐treatment EM Vital, S Dass, AC Rawstron, MH Buch, V Goeb, K Henshaw, ... Arthritis & Rheumatism 62 (5), 1273-1279, 2010 | 168 | 2010 |
| A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features YM El-Sherbiny, A Psarras, MY Md Yusof, EMA Hensor, R Tooze, ... Scientific reports 8 (1), 5793, 2018 | 116 | 2018 |
| Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus MYM Yusof, D Shaw, YM El-Sherbiny, E Dunn, AC Rawstron, P Emery, ... Annals of the rheumatic diseases 76 (11), 1829-1836, 2017 | 112 | 2017 |
| Brief report: responses to rituximab suggest B cell–independent inflammation in cutaneous systemic lupus erythematosus EM Vital, M Wittmann, S Edward, MY Md Yusof, H MacIver, CT Pease, ... Arthritis & Rheumatology 67 (6), 1586-1591, 2015 | 107 | 2015 |
| Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status MYM Yusof, A Psarras, YM El-Sherbiny, EMA Hensor, K Dutton, ... Annals of the rheumatic diseases 77 (10), 1432-1439, 2018 | 106 | 2018 |
| Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases MY Md Yusof, EM Vital, DM McElvenny, EMA Hensor, S Das, S Dass, ... Arthritis & Rheumatology 71 (11), 1812-1823, 2019 | 105 | 2019 |
| Reduced‐dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion EM Vital, AC Rawstron, S Dass, K Henshaw, J Madden, P Emery, ... Arthritis & Rheumatism 63 (3), 603-608, 2011 | 102 | 2011 |
| Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register EM McCarthy, E Sutton, S Nesbit, J White, B Parker, D Jayne, B Griffiths, ... Rheumatology 57 (3), 470-479, 2018 | 93 | 2018 |
| Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity A Psarras, A Alase, A Antanaviciute, IM Carr, MY Md Yusof, M Wittmann, ... Nature communications 11 (1), 6149, 2020 | 89 | 2020 |
Paul EmeryProfessor Rheumatology Leeds, BirminghamMelbourneVerified email at leeds.ac.uk
